Business
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi®1€22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, respectivelyUnchanged cash runway until early Q4 2026Filing of the 2025 Universal Registration Document is postponed to no later than May 28, 2026 NANTES, France, April 30, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today reported i
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AOAi8WsF_WG0drr4jQwesQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi®1","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"€22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, respectively","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Unchanged cash runway until early Q4 2026","length":41,"tagName":"p"}]},{"val":[{"type":"text","content":"Filing of the 2025 Universal Registration Document is postponed to no later than May 28, 2026","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":360,"olType":false},{"type":"text","content":"NANTES, France, April 30, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today reported its full year 2025 unaudited consolidated financial results, as approved by the Board of Directors on April 29, 2026. Audit procedures by the Company’s statutory auditors on the Company’s 2025 consolidated financial statements are still ongoing.","length":403,"tagName":"p"},{"type":"text","content":"Full Year 2025 Consolidated Financial Results (IFRS, unaudited)","length":63,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:506.46875px;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"width:122.296875px;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"width:122.296875px;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:506.46875px;border-bottom:solid black 1pt;","val":[{"type":"text","content":"In million euros","length":16,"tagName":"p","attribs":{}}]},{"style":"width:122.296875px;v...